Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone

C.J. Bailey, Brian Green, P.R. Flatt

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Importance of the field: Type 2 diabetes is typically associated with insulin resistance and dysfunction of insulin-secreting pancreatic beta-cells. Addressing these defects often requires therapy with a combination of differently acting antidiabetic agents. A potential novel combination in development brings together the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin with the thiazolidinedione pioglitazone into a fixed-dose single-tablet combination. The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity.
Original languageEnglish
Pages (from-to)1017-1025
Number of pages9
JournalExpert opinion on investigational drugs
Volume19
Issue number8
DOIs
Publication statusPublished - Aug 2010

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone'. Together they form a unique fingerprint.

  • Cite this